Living well after breast cancer randomized controlled trial protocol: evaluating a telephone-delivered weight loss intervention versus usual care in women following treatment for breast cancer by unknown
STUDY PROTOCOL Open Access
Living well after breast cancer randomized
controlled trial protocol: evaluating a
telephone-delivered weight loss
intervention versus usual care in women
following treatment for breast cancer
Marina M. Reeves1*, Caroline O. Terranova1, Jane M. Erickson1, Jennifer R. Job1, Denise S. K. Brookes1,2,
Nicole McCarthy3, Ingrid J. Hickman4,5, Sheleigh P. Lawler1, Brianna S. Fjeldsoe1, Genevieve N. Healy1,6,7,
Elisabeth A. H. Winkler1, Monika Janda8, J. Lennert Veerman1, Robert S. Ware1, Johannes B. Prins5, Theo Vos9,
Wendy Demark-Wahnefried10 and Elizabeth G. Eakin1
Abstract
Background: Obesity, physical inactivity and poor diet quality have been associated with increased risk of breast
cancer-specific and all-cause mortality as well as treatment-related side-effects in breast cancer survivors. Weight
loss intervention trials in breast cancer survivors have shown that weight loss is safe and achievable; however, few
studies have examined the benefits of such interventions on a broad range of outcomes and few have examined
factors important to translation (e.g. feasible delivery method for scaling up, assessment of sustained changes,
cost-effectiveness). The Living Well after Breast Cancer randomized controlled trial aims to evaluate a 12-month
telephone-delivered weight loss intervention (versus usual care) on weight change and a range of secondary
outcomes including cost-effectiveness.
Methods/design: Women (18–75 years; body mass index 25–45 kg/m2) diagnosed with stage I-III breast cancer in
the previous 2 years are recruited from public and private hospitals and through the state-based cancer registry
(target n = 156). Following baseline assessment, participants are randomized 1:1 to either a 12-month telephone-delivered
weight loss intervention (targeting diet and physical activity) or usual care. Data are collected at baseline, 6-months
(mid-intervention), 12-months (end-of-intervention) and 18-months (maintenance). The primary outcome is change in
weight at 12-months. Secondary outcomes are changes in body composition, bone mineral density, cardio-metabolic
and cancer-related biomarkers, metabolic health and chronic disease risk, physical function, patient-reported outcomes
(quality of life, fatigue, menopausal symptoms, body image, fear of cancer recurrence) and behaviors (dietary intake,
physical activity, sitting time). Data collected at 18-months will be used to assess whether outcomes achieved
at end-of-intervention are sustained six months after intervention completion. Cost-effectiveness will be
assessed, as will mediators and moderators of intervention effects.
Discussion: This trial will provide evidence needed to inform the wide-scale provision of weight loss, physical
activity and dietary interventions as part of routine survivorship care for breast cancer survivors.
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Background
Breast cancer is the most common invasive cancer diag-
nosed among women in developed countries and the
second most common cause of cancer death [1]. High
incidence and high overall survival (between 80 and
90 % relative 5-year survival in most developed countries
[1]) have resulted in a growing number of breast cancer
survivors worldwide. Addressing survivorship issues for
these women is important for improving quality of life
and health outcomes, and for reducing burden on the
health care system.
Excess body weight, physical inactivity, and poor diet
quality are prevalent among breast cancer survivors,
both prior to and following diagnosis and treatment,
with over 60 % of survivors overweight or obese; over
60 % insufficiently active; and, over 80 % consuming in-
adequate amounts of fruit and vegetables [2–5]. These
factors have been associated with poor outcomes (breast
cancer-specific and all-cause mortality) [6–9] and an in-
creased risk of treatment-related side-effects [10–15].
Obesity management has been identified as a priority
area for cancer survivors, with breast cancer survivors
being a sub-group where an obesity link with cancer
progression appears particularly important [16].
A small but growing number of weight loss interven-
tion trials in breast cancer survivors [17–20] have shown
that modest weight loss is safe and achievable, and can
improve some treatment-related side-effects as well as
women’s quality of life in the short-term. However, a
number of gaps in this evidence base remain, including:
i) understanding the benefits of weight loss across a
broader range of outcomes, i.e., assessment of hard
endpoints (such as survival), intermediate biomarkers,
co-morbidities, and patient-reported outcomes; ii) evalu-
ating interventions that are: feasible to deliver and
implement in routine practice, convenient and flexible
to the patient, and that result in sustained behavior and
weight change; iii) assessing economic outcomes; and,
iv) identifying sub-groups of the population who benefit
the most from particular interventions to inform a per-
sonalised approach to weight management [16, 21].
Comparisons of interventions against usual care are still
warranted, particularly when examining patient-reported
outcomes and treatment-related side-effects, as these
may naturally improve over time following treatment
completion. Comparison of cost-effectiveness against
current practice (i.e., usual care) also is needed to inform
translation into practice and allocation of scarce health
care resources.
The Living Well after Breast Cancer trial aims to
address a number of these gaps. This randomized con-
trolled trial is evaluating a telephone-delivered weight loss
intervention versus usual care in women following treat-
ment for breast cancer. Specifically, the trial aims to:
– evaluate the effect of the intervention compared
with usual care on percent change in weight at
end-of-intervention (primary outcome); and changes
in body composition, bone mineral density,
cardio-metabolic and cancer-related biomarkers,
metabolic health and chronic disease risk, physical
function, patient-reported outcomes (quality of
life, fatigue, menopausal symptoms, body image,
fear of cancer recurrence) and behaviors (dietary
intake, physical activity, sitting time) (secondary
outcomes);
– assess whether changes in the primary and
secondary outcomes are sustained six months after
the end of the intervention;
– evaluate the cost-effectiveness of the weight loss
intervention compared to usual care;
– identify subgroups who achieve the greatest benefit
from the intervention (based on demographic,
social and clinical characteristics, cancer-related
characteristics and genomic profiles); and
– explore mediators and moderators of the
intervention on primary and secondary outcomes to
understand how the intervention worked.
Methods
Study design
Living Well after Breast Cancer is a two-arm parallel
group randomized controlled trial evaluating a
12-month telephone-delivered weight loss intervention
versus usual care in women diagnosed with breast cancer.
An overview of the study design and the schedule for en-
rollment and study assessments is shown in Table 1.
Ethical approval was granted from the human research
ethics committees of Greenslopes Private Hospital (12/26),
Royal Brisbane and Women’s Hospital (HREC/12/QRBW/
149), St. Vincent’s Health & Aged Care (13/02); and The
University of Queensland Medical Research Ethics
Committee (2012000944). A copy of the latest version
of the study protocol approved by the ethics committees
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is included as Additional File 1. Approval was also granted
from the Queensland Health Director General for acces-
sing confidential information through the state-based can-
cer registry (RD004777). The trial was prospectively
registered with the Australian New Zealand Clinical Trials
Registry (www.anzctr.org.au; ACTRN12612000997853).
Eligibility criteria
Inclusion criteria are: female, stage I-III breast cancer
diagnosed within the previous 2 years (based on cancer
registry pathology data), aged 18–75 years, body mass
index (BMI) 25–45 kg/m2, and completed primary treat-
ment (i.e., surgery, chemotherapy or radiotherapy). Con-
tinued hormonal treatment is permitted. Exclusion
criteria are: pregnant; contraindications to participating
in an unsupervised program (e.g., unstable heart disease,
breathing problems requiring hospitalization in the last
6 months, undergoing dialysis, planning a knee or hip
replacement in the next 6 months, regular use of a
mobility aid); taking pharmacological doses of warfarin;
Table 1 Schedule of enrollment, intervention, and assessment
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greater than 5 % weight loss in previous 6 months; insuf-
ficient English to complete assessments and participate
in the intervention; unable to travel to Brisbane to
complete study assessments; or self-reporting depres-
sion, anxiety or other mental health condition as a
current significant problem that would interfere with
study participation. Women who develop a recurrence
during the study period are withdrawn from the study.
Participant recruitment
Participants were recruited through seven Brisbane
hospital sites (Royal Brisbane and Women’s Hospital,
Redcliffe Hospital, Mater Public Hospital, Mater Private
Hospital, Greenslopes Private Hospital, North West
Private Hospital, and Holy Spirit Northside Private
Hospital; between October 2012 and June 2013), and
through the state-based cancer registry (between July
2013 and December 2014). At hospital sites, nursing
staff (e.g., breast care nurses, cancer care coordinators)
provided potential participants with a study information
packet during a routine consultation and briefly in-
formed them of the study. The information packet
contained a patient information brochure and consent
to contact form with a reply-paid envelope. Interested
women returned the form to their nurse or clinician or
posted it directly to the research team. At one hospital
site, nursing staff identified potentially eligible women
from hospital records and posted the study information
packet following confirmation of vital status against the
state-based death register. Potentially eligible women
diagnosed with breast cancer (based on age, stage of
disease and residing within a 100 km radius of Brisbane)
between 1 July 2013 and 30 June 2014, were identified
through the Queensland Cancer Registry. Consistent
with protocols for recruitment through the cancer regis-
try, oncology care physicians identified from registry
notifications, were first sent a letter to gain consent for
patient contact. Physicians providing approval signed a
letter informing their patient of the study, which was
posted along with the patient information brochure,
the consent to contact form and a reply-paid enve-
lope. Additional recruitment methods included: post-
ers placed in participating hospitals, word-of-mouth,
and institution newsletters.
Screening and consent
Women who are interested in hearing further about the
study (i.e., return the consent to contact form) are
posted an information sheet and consent form and are
telephoned by study staff to explain the study, answer
any questions, and screen for eligibility. Screening for
BMI is based on self-reported height and weight.
Women still undergoing primary treatment, but who are
interested in the study, are contacted after treatment
completion. Those who are eligible and interested pro-
vide signed informed consent.
Randomization, allocation and blinding
The randomization sequence was generated using a
computer-generated randomization program, with un-
even block sizes ranging from four to 10 (www.randomi-
zation.com), by a staff member not otherwise involved
with the study, and remained concealed from the study
team. Following completion of baseline data collection,
the project manager is notified of individuals’ allocation
to study groups (randomized 1:1 into intervention or
usual care) by the staff member responsible for the allo-
cation sequence. In instances where participants have
family or close friends already participating in the trial,
participants are manually allocated (yoked) to the same
study group as their family member or friend in order to
prevent potential contamination. All assessors are
blinded to participants’ study group allocation.
Weight loss intervention
The weight loss intervention is based on clinical practice
guidelines for overweight and obesity [22, 23] and rec-
ommendations for cancer survivors [24, 25], and has
been previously pilot tested [26, 27]. The intervention
uses a combined approach of increasing physical activity,
reducing energy intake and behavior therapy (i.e., use of
behavior change strategies), delivered by lifestyle coaches
(accredited practising dietitians with additional study-
specific training in exercise promotion), and aims for
modest weight loss of between 5 and 10 %.
Intervention targets
Physical activity Participants are encouraged to grad-
ually increase activity, aiming for at least 210 min per
week of planned (aerobic) activity at a moderate-to-
vigorous intensity (30 min each day; if possible, increas-
ing to 45–60 min/day), and 2–3 sessions of resistance
exercise per week. These recommendations are consist-
ent with physical activity guidelines for weight loss and
weight loss maintenance, both generally [28] and specif-
ically among cancer survivors [24, 25, 29]. Rather than
being provided with a structured exercise program, par-
ticipants identify planned activities that they enjoy and
that can easily be incorporated into their lifestyle (e.g.,
walking, swimming, exercise classes), to meet the aer-
obic activity target. Participants who choose to do their
resistance exercises at home are provided with detailed
instructions and diagrams on home-based resistance
exercises, including exercises using dumbbells and some
without. In addition, participants are encouraged to in-
crease their incidental/everyday activity (e.g., gardening,
taking the stairs, housework), and reduce their sitting
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time (i.e., to get up and move at least every 30 min and
to aim for no more than 2 h per day of screen time, out-
side of work hours). Participants are provided with a
pedometer and encouraged to achieve 10,000 steps each
day. This is consistent with evidence regarding the
health consequences, notably cardio-metabolic, regard-
ing high levels of sedentary time [30, 31], and the health
benefits of increasing time spent in physical activities of
any intensity [32, 33].
Dietary intake Participants are encouraged to reduce
energy intake by approximately 2000 kJ per day through a
prescribed recommended kilojoule intake (between 5,000
and 7,500 kJ/day) based on age and baseline weight [34].
They are also encouraged to improve diet quality. Inter-
vention strategies focus on portion control (by reducing
portion size or number of serves) and reducing energy
density, along with self-monitoring of food (and energy)
intake. In addition, participants are encouraged to aim for:
five serves per day of vegetables and two serves per day of
fruit; total fat intake ≤30 % of energy; saturated fat intake
<7 % of energy; and, limit alcohol intake to one standard
drink per day (with at least two alcohol-free days per
week), consistent with general dietary recommendations
for weight management [22, 23] as well as specific recom-
mendations for cancer survivors [24, 25].
Behavior therapy Behavior change strategies and princi-
ples used to guide the intervention are evidence-based
and derived from Social Cognitive Theory [35], which
emphasizes self-monitoring, goal setting, problem solv-
ing, social support, stimulus control, positive self-talk
and self-reward.
Intervention Protocol
The intervention is delivered entirely remotely, with no
face-to-face contact, and involves: telephone coaching
calls, a posted workbook and materials, and optional
supportive text-messages. Intervention participants also
receive a copy of a newsletter from the national breast
cancer consumer organisation and a study newsletter after
each assessment. In addition, participants are provided
with written feedback following each assessment compar-
ing their assessment results (body composition, dietary
intake, physical activity, blood test results) to recommen-
dations. Telephone coaches use baseline feedback to
assess participants’ status at the commencement of the
intervention and feedback from follow-up assessments to
monitor their progress. The 12-month intervention in-
cludes: an initial intensive 6-month phase, followed by a
6-month extended care phase (see Table 2).
Initial intensive phase of intervention (months 1–6)
The focus of the initial intensive phase (weekly and
fortnightly coaching calls over 6-months) is to build rap-
port, provide education about the importance of physical
activity, healthy eating and weight management (by
working through workbook content both during and
in-between calls), encourage skill building through self-
monitoring and goal setting, and work towards behavior
change and weight loss (see Table 2). During this phase,
participants receive up to 16 calls (6 × weekly calls,
10 × fortnightly calls) as well as optional text messages.
Telephone call timing is scheduled based on participant
preference (day vs. night). Participants also receive a
detailed workbook, set of digital scales, measuring tape,
pedometer, calorie counter book and self-monitoring
diary, which is referred to throughout the intervention.
Lifestyle coaches use a motivational interviewing
counseling style [36], with a semi-structured approach in
relation to both call contact and content (e.g., the order
in which intervention targets are addressed) based on
participant preference. The protocol for each call in-
cludes: assessment of progress; problem solving; advice/
education; collaborative goal setting; and development of
a behaviorally-specific action plan. Call outlines and
checklists are used by coaches to facilitate intervention
fidelity. Fortnightly supervision meetings and audio-
recording of randomly selected calls are used to monitor
and maintain intervention fidelity, provide coaches with
feedback throughout the intervention delivery period,
and to discuss participants with particular challenges.
Participants also have the option to receive mobile
phone text messages during this initial phase, starting
from the second phone call. This aspect of the interven-
tion is based on prior research on the use of mobile
phone text messages for supporting and maintaining
behavior changes and weight loss [27, 37]. In the initial
phase, the participant, in consultation with the coach,
determines the content and timing of the text messages.
The texts are created (maximum of 160 characters) and
sent using a web-based platform that enables the coa-
ches to pre-schedule texts to send at specific times and
days. Coaches received training on how to introduce the
text messages and were provided with examples on the
types of content they could include. All messages are
personalized with the participant’s first name and signed
off by the coach.
Extended care phase of intervention (months 7–12)
The focus of the 6-month extended care phase (6 ×
monthly calls) is to review progress, problem solve, and
identify barriers and solutions to maintaining weight
loss, physical activity and dietary changes. During this
phase participants are encouraged to receive text mes-
sages between calls (regardless of whether they received
texts during the initial phase). During the extended care
phase, a more structured approach for text content and
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timing is used, with the texts designed to target specific
behavioral skills: 1) prompting self-monitoring of weight;
2) behavioral goal setting; and, 3) prompting real-time
behaviors (see Table 3 for examples). Each text type has
a suggested frequency (Table 3), but is tailored to the
participant’s preferences. The total number of text mes-
sages that can be received is in the range of two to 16
per fortnight (i.e. every two weeks). Participants who opt
to receive the text messages during this phase first
complete a scripted interview to collect information for
tailoring the text messages. Text message content is
tailored to: the names of the participant and coach,
behavioral goals, rewards for reaching goals, identified
barriers (and solutions) for reaching goals, preparatory
behaviors to reach their goals, and outcome expectan-
cies. Throughout this phase, tailoring information for
the text messages is updated as requested by the partici-
pants or suggested by the coach.
Usual care
Participants in the usual care group continue to receive
their standard medical care. In addition, these partici-
pants are posted materials after each of their study as-
sessments (baseline, 6-months, 12-months, 18-months),
which includes brief written feedback from their study
assessment, a copy of a newsletter from the national
breast cancer consumer organisation and a study news-
letter. The feedback following study assessments is simi-
lar to that provided to intervention participants with the
exception that participants’ results are not compared to
national and study recommendations.
Data collection
Data are collected from all participants at baseline,
6-months (mid-intervention), 12-months (end-of-inter-
vention) and 18-months (follow-up after 6-months of no
contact) by research staff blinded to participants’ study
group (see Table 1). Each assessment involves: a clinic
visit, blood sample collection, two telephone interviews,
a self-administered questionnaire, and objective moni-
toring of physical activity by accelerometry for 7 days.
The clinic visit includes objective measurements of
height, weight, waist and hip circumferences, body com-
position, bone mineral density, blood pressure, and
performance-based measures of physical function. Par-
ticipants attend their local pathology collection centre
after at least a 10-h fast to have blood samples (18 mL)
taken by trained phlebotomists. Assays are conducted on
fresh samples with serum samples also frozen at −80 °C
for batch assays. Telephone interviews collect data on:
Table 2 Overview of intervention content
Intervention phase & call frequency Purpose Objectives
Initial phase
6 weekly calls






• Feedback on baseline assessment
to build motivation
• Understand importance of physical
activity and diet in weight loss
management
• Build patient engagement through
homework and self-monitoring
• Use of behavior change skills and
action plans: goal setting, self-monitoring,
problem solving, rewarding success




Optional text (SMS) messages
Establish behavior change
& achieve weight loss
Skill-building
• Reflect on progress (changes made)
and outcomes/benefits experienced
• Progress goals
• Continued use of behavior change
skills: goal setting, self-monitoring,





Optional structured text (SMS) messages
Consolidation
Maintaining changes
• Encourage participants to direct sessions
• Reinforce successes and review benefits
• Behavior change skills: relapse prevention
and maintaining motivation
• Plans and strategies for maintaining weight
loss and behavior changes
SMS short-messaging service
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physical activity levels, dietary intake, breast cancer-
related information, and demographic and health charac-
teristics. The self-administered questionnaire collects
information on patient-reported outcomes and a range of
constructs related to social-cognitive theory. Physical
activity is also objectively measured via two activity moni-
tors (one worn on the hip and one on the thigh), fitted at
the clinic visit. Tumor characteristic data are obtained from
pathology notifications within the cancer registry. Data re-
lated to intervention delivery are tracked in the study data-
base. This includes data on call outcomes (call completion
versus missed calls), call duration and call content (via a
checklist of topics). A summary of study outcomes and data
collection methods and tools is shown in Table 4. All staff
received detailed training in data collection protocols and
are blinded to participants’ study arm. Where appropriate,
measurements are taken at least in duplicate.
Primary outcome
The primary outcome is change in weight (% initial body
weight). At each visit, weight is measured in duplicate to
the nearest 0.1 kg, without shoes or heavy clothing,
using calibrated scales (Tanita BWB-600 Wedderburn
Scales, Australia), with the mean of the two values
recorded.
Secondary outcomes
Secondary outcomes include: anthropometry (waist and
hip circumference), body composition, bone mineral
density, cardio-metabolic and cancer-related blood
markers, metabolic health (blood pressure and metabolic
syndrome), performance-based measures of physical
function, patient-reported outcomes (quality of life,
fatigue, menopausal symptoms, body image, fear of can-
cer recurrence, arthralgia, chemotherapy-induced per-
ipheral neuropathy), behavioral changes (dietary intake,
physical activity, sitting time), and cost-effectiveness.
Anthropometry
Height is measured in duplicate to the nearest 0.1 cm
using a stadiometer (Magnimeter, Raven Equipment,
UK) at baseline. Waist and hip circumference are
measured in duplicate to the nearest 0.5 cm using a
non-expandable tape measure at the superior border
of the iliac crest [38] and the greatest gluteal protu-
berance, respectively, following a normal expiration. A
third measurement is taken if measures differ by
more than 1.0 cm. The mean of all measurements
taken is used.
Body composition & densitometry
Body composition and bone mineral density are ac-
quired by Lunar Prodigy Dual-energy X-ray Absorpti-
ometry (DXA; GE Medical Systems, LUNAR,
Madison, WI, USA), using the manufacturer’s stand-
ard procedures. Daily calibration of the DXA is per-
formed on the morning prior to each measurement
using an aluminium spine phantom. All images are
acquired and analysed by a trained technician (DSKB)
using the manufacturer’s proprietary software (en-
CORE, version 14.1). Measures of body composition
(fat mass (FM, g), percent fat (% region), fat free
mass (FFM, g), and lean body mass (LBM, g; proxy
for muscle mass)) are acquired from the total body
scans. Total body scans provide measures of whole
and regional body composition. Appendicular lean
mass (LBM in arms and legs separated from trunk
LBM) is calculated and used in the assessment of
sarcopenia [39, 40].
Bone mineral density (BMD, g/cm2), bone mineral
content (g) and bone area (cm2) for total body, anterior-
posterior lumbar spine (LS 1–4) and bilateral proximal
femur sites are measured. All BMD values are calculated
as T- and Z-scores using the Geelong Osteoporosis
Study reference database [41], for all sites.
Table 3 Examples of types of structured text messages that could be received during the extended care phase of the intervention
(months 7 – 12)
Text message type Behavior change strategies targeted Example text messages Frequency
Self-monitoring weight Self-regulation; Satisfaction
with perceived outcomes
Keeping track of ur weight is important
2 maintain progress & catch ‘slips’ Jane.
Weigh yourself today & write it down in
ur Living Well Diary. Jenny
1 per week or fortnight
Goal check Self-regulation; Satisfaction
with perceived outcomes
Hi Jane. Did u achieve ur goal 2 have 3
alcohol free days this week? Text me back
yes or no so I know how u r going. Jenny
1 per week or fortnight
per goal
Goal check reply Self-regulation; Outcome
expectancy; Satisfaction
with perceived outcomes;
Self efficacy; Social support
Wonderful news Jane! Remember how
good u feel achieving ur goal & use this
as motivation on ur ‘off’ days. Keep it up! Jenny
Only sent if participant responds
to goal check
Behavior prompt Think ahead Jane. U want 2 do 30 min on
the treadmill 6× this week so make sure u
set the alarm for the morning. Jenny
Up to 2 messages per week
per goal
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Cardio-metabolic and cancer-related biomarkers
Glucose, glycated haemoglobin (HbA1c), total choles-
terol, high density lipoprotein (HDL) cholesterol, low
density lipoprotein (LDL) cholesterol and triglycerides
are measured in fresh blood. HbA1c is measured from
whole blood samples by the high performance liquid
chromatography method (ion-exchange with ultraviolet
detection; D-100 analyser, Biorad Laboratories, Hercules,
CA, USA). Glucose, triglycerides, total cholesterol and
HDL cholesterol are measured by an enzymatic colori-
metric assay with Abbott c16000 Clinical Chemistry
Analyzer (Abbott Diagnostics, Abbott Park, IL, USA).
LDL cholesterol is calculated using the Friedewald equa-
tion [42].
Aliquots of serum, plasma and buffy coat are stored
frozen at −80 °C to allow analysis of other relevant blood
markers – for example insulin, adipokines (total and high
molecular weight adiponectin, leptin), inflammatory
markers (e.g., high-sensitivity C-reactive Protein), and
genomic markers (e.g., microRNAs). All samples will be
measured in duplicate with repeated samples from indi-
viduals assayed together to avoid batch variation.
Table 4 Primary and secondary outcomes and assessment methods
Outcome Collection method Assessment tool
Primary outcome
Weight Clinic visit Tanita BWB-600 Wedderburn Scales
Secondary outcomes
Anthropometry
Waist circumference Clinic visit Non-expandable tape measure
Hip circumference Clinic visit Non-expandable tape measure
Body composition & densitometry
Body composition (FM, FFM, LBM) Clinic visit Lunar Prodigy DXA - Total body and regional
Bone mineral density Clinic visit Lunar Prodigy DXA – Anterior-posterior lumbar
spine (L1-L4); Bilateral proximal femur.
Cardio-metabolic & cancer-related biomarkers
Glucose, lipids, HbA1c Fasting blood test Standard assays on fresh blood
Other cardio-metabolic and
cancer-related blood markers
Fasting blood test Stored serum, plasma, buffy coat
Metabolic health & chronic disease risk
Blood pressure Clinic visit Welch Allyn 300 Series Vital Signs Monitor
Physical functioning
Hand grip strength Clinic visit Smedley dynamometer
Timed chair stands Clinic visit 5 stopwatch timed sit-to-stand transitions
Patient-reported outcomes
Quality of life SAQ PROMIS Global Health Scale [50]
Fatigue SAQ Functional Assessment of Chronic Illness
Therapy – Fatigue Scale (FACTIT-Fatigue) [51]
Menopausal symptoms SAQ Greene Climacteric Scale [53]
Body image SAQ Body Image and Relationships Scale (BIRS) [56]
Fear of cancer recurrence SAQ Concerns about Recurrence Questionnaire – 4-items
(CARQ-4) [58]
Arthralgia SAQ Breast Cancer Prevention Trial Symptom
Scale – Musculoskeletal Pain subscale [59]
Peripheral neuropathy SAQ Patient Neurotoxicity Questionnaire (PNQ) [61, 62]
Behavioral outcomes
Dietary intake Telephone interview 2 × 24-h dietary recalls
Physical activity Objectively collected,
Telephone interview
Actigraph GT3X+ tri-axial accelerometer
Active Australia Survey [69]
Sitting time Objectively collected activPAL3TM monitor
DXA Dual-energy X-ray Absorptiometry, FFM fat-free mass, FM fat mass, HbA1c, glycated hemoglobin, LBM, lean body mass, SAQ, self-administered questionnaire
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Metabolic health & chronic disease risk
Blood pressure is measured seated using an automated
blood pressure monitor (300 Series Vital Signs Monitor,
Welch Allyn, Beaverton, OR, USA) with appropriately
sized cuff. Measurements are taken in duplicate, with a
third taken if the first two differ by ≥10 mmHg systolic
or ≥6 mmHg diastolic, or if the first two readings are
more than 140 mmHg/90 mmHg. The mean of the read-
ings is recorded.
Comorbidities are assessed using the Charlson Comor-
bidity Index based on self-reported diagnosis of 13 con-
ditions during the telephone interview [43, 44].
Participants also self-report if they have ever been diag-
nosed with hypertension [45]. Metabolic syndrome is
classified according to the International Diabetes Feder-
ation worldwide consensus definition [46] and examined
continuously [47, 48]. Current use of blood pressure,
lipid lowering and/or diabetes medications are self-
reported during the telephone interview. Comorbidities
and medication use are assessed at baseline and each
follow-up visit.
Performance-based measures of physical function
Hand grip strength and timed chair stands are used to
assess upper and lower body function, respectively, as
they have shown good to excellent reliability and high
discrimination across different functional levels [49]. Bi-
lateral hand grip strength (kg) is measured using a hand-
held dynamometer (Smedley, Scandidact, Denmark),
with participants standing in neutral position with elbow
flexed at 90°, the forearm in neutral and wrist held be-
tween 0 and 30° dorsiflexion and 0–15° ulnar deviation.
Three measurements are conducted on each hand, alter-
nating hands with a rest period in between measure-
ments to prevent fatigue. Five chair stands are timed
using a stopwatch. Participants are asked to perform, as
quickly and ably as possible, five repetitions from a
seated position to a fully standing position with arms
crossed over their chest.
Patient-reported outcomes
Quality of life is measured using the 10-item Patient
Reported Outcome Measurement Information System
(PROMIS) Global Health Scale which asks partici-
pants to evaluate their general health across five do-
mains (physical function, fatigue, pain, emotional
distress and social health) as well as general health
perceptions. Items are scored into a Global Physical
Health component and Global Mental Health compo-
nent with higher scores indicating better functioning.
The component scores have shown good internal
consistency and good relative validity compared to
EQ-5D [50].
Fatigue is measured using the 13-item Functional As-
sessment of Chronic Illness Therapy – Fatigue Scale
(FACIT-Fatigue) which assesses fatigue over the last
seven days on a 5-point scale (0 = not at all to 4 = very
much) [51]. Items are summed, giving a score of 0–52,
with higher scores indicating lower fatigue. Fatigue is
classed as present if the FACIT-Fatigue score is <34, cor-
responding to ICD-10 criteria for fatigue [52].
Menopausal symptoms are measured using the 21-item
Greene Climacteric Scale [53], which assesses the extent
to which participants are affected by specified meno-
pausal symptoms at present. Items are answered on a
modified 5-point response scale from ‘none’ to ‘very
severe.’ Responses of ‘severe’ and ‘very severe’ are col-
lapsed to correspond to ‘extremely’ on the original 4-
point response scale. Items are summed to create a total
score as well as three subscale scores – psychological
symptoms, somatic symptoms, vasomotor symptoms –
with higher scores indicating more severe symptoms
[53]. The total scale has shown excellent internal
consistency, subscale scores have shown good two week
test-retest reliability and are sensitive to change [54, 55].
Body image is measured using the 32-item Body Image
and Relationships Scale (BIRS), a scale developed specif-
ically for women who have been diagnosed and treated
for breast cancer [56]. The BIRS has shown good reli-
ability, convergent and divergent validity, and sensitivity
to change [56, 57]. Items are scored on a 5-point scale
(1 = strongly disagree to 5 = strongly agree), with items
summed to yield a total score and three subscale
scores – strength and health; social barriers; sexuality
and appearance – with higher scores indicating
greater impairment.
Fear of cancer recurrence is measured using the 11-
point 4-item Concerns about Recurrence Questionnaire
(CARQ-4) [58]. The four items are summed, giving a
score of 0–40, with higher scores indicating greater fear.
The CARQ-4 has shown good two week, test-retest reli-
ability, and demonstrated concurrent and convergent
validity with good correlations against the Fear of Cancer
Recurrence Inventory and moderate correlations with
measures of depression and anxiety [58].
Arthralgia is measured using the Breast Cancer Preven-
tion Trial Symptom Scale - Musculoskeletal Pain sub-
scale, which includes three items assessing general aches
and pains, joint pains and muscle stiffness over the past
4 weeks [59]. Items are scored on a 5-point severity scale
from 0 ‘not at all’ to 4 ‘extremely,’ with scores from the
three items averaged such that higher scores indicate a
greater degree of being bothered by pain. The subscale
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has shown good internal consistency and is sensitive to
change [59, 60].
Chemotherapy-induced peripheral neuropathy (CIPN)
is measured using the Patient Neurotoxicity Question-
naire (PNQ) [61, 62] in the subset of participants who
were treated with chemotherapy. The PNQ includes two
items assessing the presence and severity of sensory and
motor disturbances over the past 7 days. Each item is
rated on a 5-point scale from 0 ‘no neuropathy’ to 4
‘severe neuropathy,’ with each item considered separately
[63]. The PNQ scores show good concurrent validity
against more detailed scales of CIPN [62] and are sensi-
tive to changes over time [62, 63].
Behavioral outcomes
Physical activity and sedentary time are measured ob-
jectively at each assessment with the tri-axial Actigraph
GT3X+ accelerometer (ActiGraph, Pensacola, Florida)
and the activPAL3TM monitor (PAL Technologies Lim-
ited, Glasgow, UK), each worn for seven consecutive
days. Participants record sleep time and monitor
removal times in a logbook. The Actigraph GT3X+ is
worn positioned over the right hip via an adjustable elas-
tic belt. Participants are asked to wear this monitor
during all waking hours and to remove it only for sleep
and during times the monitor could be damaged (e.g.,
during water-based activities). The activPAL is water-
proofed, attached to the anterior mid-line of the right
thigh using a hypoallergenic adhesive patch and worn
continuously across the 7-day wear period, for 24 h per
day (during waking and sleeping hours). Additional
patches are provided to replace as necessary. The activ-
PAL monitor records triaxial acceleration at 10Hz, from
which thigh position, and the start and end of each
period of time spent sitting/reclining, standing and
stepping, are determined, along with transitions from sit-
ting to standing and stepping speed. The activPAL has
been shown to be a valid monitor for measuring sedentary
behavior and is sensitive to detecting change [64]. The
Actigraph GT3X+ monitor has shown acceptable relative
validity when compared to oxygen consumption [65].
Raw GT3X+ data are collected at 30Hz and downloaded
in Actilife (v 6.6.3). Both 10-s and 60-s epoch files are
processed in SAS version 9.4. Non-wear time (estimated
as blocks of ≥60 min of 0 counts per minute (cpm) with
up to 2 min with counts 1–49 cpm) is removed [66]. Non-
wear (invalid) days are also removed (<10 h wear or be-
fore/after the monitoring period based on the logbook).
When quality controls (data visualisation and the logbook
data) indicate participants wore the monitor to bed, self-
reported sleep and naps are also removed. All minutes with
≥1952 cpm [67] are classed as moderate- to vigorous-
intensity physical activity (MVPA), then summed for each
day and averaged across valid days (i.e., ≥10 h of wear).
The activPAL data are downloaded using activPAL
Professional 7.3.32 software (PAL Technologies Limited,
Glasgow, UK). Recorded bouts of activity (sitting/reclining,
standing and stepping) are processed in SAS version 9.4,
using the monitor and logbook data with quality controls
(data visualisation and cross-checking against the logbook).
Unreported wake/sleep times are estimated by staff from
times when movement first began/last ceased. All time dur-
ing bouts that are ≥50 % during a self-reported sleep,
removal or nap period are initially classed as sleep, removal,
or a nap. Sleep periods are then adjusted to begin/end with
the first/last sitting/reclining bout of ≥20 min duration dur-
ing each period initially identified as sleep. Total sitting
time (i.e., sitting/reclining during waking wear time) is
summed for each day then averaged on valid days. Days are
defined from wake on one day until wake the next day.
Days are classed as valid if removals constituted <20 % of
waking hours, and, when sleep/wake times are not re-
ported, if waking wear time was ≥10 h. These methods are
consistent with previous reports [68].
Physical activity is also self-reported using the Active
Australia Survey, an 8-item questionnaire which assesses
times spent walking, in moderate and in vigorous activities,
and doing household and gardening activities, over the past
week [69]. As per standard scoring protocols, self-reported
MVPA is calculated as the sum of time spent walking, in
moderate activities, and in vigorous activities (weighted by
two), with truncation at 1680 min per week to reduce over-
reporting. The Active Australia Survey has been shown to
be valid, reliable, and responsive to intervention change
[70–73]. The number of days and amount of time in the
past week spent specifically walking for exercise [74], as
well as undertaking strength or resistance based exercises,
are also collected during the telephone interview.
Dietary intake is assessed using two unprompted 24-h
dietary recall interviews (recalling one weekday and one
weekend day) conducted using FoodWorks® Interview
(version 1, 2009, Xyris Software, Brisbane, Australia), based
on a 5-stage multi-pass method [75]. Participants are
provided with a food model booklet to assist in estimating
portion sizes. Energy and nutrient intakes are derived from
dietary intake data using FoodWorks® Professional Edition
(version 6, 2009, Xyris, Brisbane, Australia) nutritional ana-
lysis software, using the average of intakes from recalled
days. Daily fruit and vegetable intake are also assessed using
two items, which have been shown to be reliable and valid
when compared to blood biomarkers [76, 77].
Potential mediating and moderating variables
Demographics
Demographic and social characteristics collected during the
baseline telephone interview include: highest educational
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attainment, employment status, household income, ethni-
city, country of birth, marital status, children living at home
and smoking status. Employment and smoking status are
both re-assessed at each follow-up assessment. Age at base-
line is determined from date of birth on pathology records.
Participants’ residential postcode was used to assess area-
level socio-economic position and geographical location/re-
moteness [78, 79].
At each assessment all participants self-report whether
they have used any particular tools to assist with weight
loss over the previous 6 months. This includes meal
replacements, food delivery (pre-prepared meals) programs,
other commercial weight loss programs (e.g. Weight
Watchers), bariatric surgery or weight loss medications.
Cancer and treatment-related information
Cancer-related details are obtained from pathology re-
cords in the cancer registry and include: date of diagno-
sis; tumor size, type and histological grade; surgery
details; receptor status (estrogen, progesterone and
HER2/neu); and, lymph node involvement. Participants
report menopausal status at diagnosis; treatments
received (surgery, chemotherapy, radiation therapy,
endocrine therapy, reconstructive surgery); treatment
completion dates; and, presence (either current or past)
of lymphedema.
Depression and anxiety
Participants self-report whether they have ‘ever been
diagnosed with depression or anxiety.’ Depressive symp-
toms are also assessed using the 8-item PROMIS Short
Form v1.0 – Depression 8b tool, which asks about nega-
tive mood, views of self and social cognition, decreased
positive affect, and engagement over the last seven days
on a 5-point scale (1 = never to 5 = always). Scores are
summed (giving a score of 8–40) and converted to a
T-score (M = 50, SD = 10) based on the U.S. general
population [80]. This depression scale has demonstrated
good reliability and validity [81].
Theory-based constructs
Data on constructs related to Social Cognitive Theory,
and targeted as part of the intervention are collected
using the self-administered questionnaire. Each of
these constructs are assessed separately for physical
activity and dietary intake, using items adapted from
previous tools which have been described in detail
elsewhere [37]. The constructs measured include
outcome expectancies [82, 83], satisfaction with out-
comes [84], self-regulation [85], self-efficacy [86, 87],
social support [88], and perceived environmental
opportunity [89–91].
Adverse events
Data on adverse outcomes are collected at each follow-
up assessment for all participants. Adverse outcomes are
defined to participants as any new health problem such
as: a breast cancer recurrence; other cancer diagnosis;
diagnosis of other medical condition; period of hospital-
isation; muscle injury or bone/joint problems; new
symptoms; or, worsening of pre-existing conditions. Ad-
verse events spontaneously reported either during inter-
vention contacts or in between assessments are also
recorded. The severity (5-categories ‘mild’ through to
'fatal') and relatedness to the intervention (5-categories
‘clearly not related’ through to ‘clearly related’) are
recorded for all adverse events reported. The relatedness
to the intervention is reported by the participant in
discussion with the interviewer, as well as with consult-
ation with the treating physician and principal investiga-
tor if needed. Unintentional weight loss is also assessed
for all participants at each follow-up assessment.
Retention strategies
A number of strategies are used to maximise retention
over the 18-month study period. Of key importance is
the development of good rapport with study staff (pro-
ject manager, lifestyle coaches and assessors). Interven-
tion calls and assessments are scheduled at times
convenient to the participant. Participants travelling
50 km or further (round trip) to attend the clinic visit
are provided with a gift card as reimbursement for their
travel costs. Car parking costs are covered for all partici-
pants. Participants are contacted 2–4 weeks prior to
their due date for the assessment to schedule their clinic
visit and other aspects of their assessment. A 45-day
window is allowed for the completion of the study
assessment. Where necessary, participants who plan to
be travelling, or are otherwise not available to complete
all of the assessment during the scheduled window,
coordinate with the project manager to complete their
assessment earlier. All participants receive a study news-
letter following each assessment and all participants are
posted birthday cards. Feedback from the study assess-
ments (e.g., bone mineral density DXA scan results) is
provided to treating doctors as requested. Participants
provide multiple contact details (e.g., mobile, home and/
or work phone and email address) along with details of
an emergency contact (family member or friend) to
minimize loss to follow-up.
Data management
Data sheets are stored in locked filing cabinets and elec-
tronic data are stored in password-protected files on a
secure network system. Access to the study database is
restricted. All data are double-key entered and checked
for inconsistencies. Where appropriate, the database
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includes automatic range checks. In addition, all data are
checked and cleaned prior to analysis.
Statistical analyses
Sample size
The sample size calculation is based on the between-
group difference in weight change (the primary out-
come) 12 months after study entry, with a minimum
clinically important difference (MCID) in weight change
of 5 % of initial body weight [24]. Conservatively, assum-
ing a standard deviation (SD) of change of 8.5 % [92],
then with alpha = 0.05 and 90 % power we will need to
collect 12-month data on 62 participants in each group
(124 total). Allowing for 20 % attrition at 12 months, 78
per group (156 participants in total) will need to be re-
cruited. With a sample size of 62 per group we will have
80 % power to detect effect sizes of 0.5 (i.e., minimum
between group difference of half a SD) for the secondary
outcomes. Of the secondary outcomes, only fatigue
(FACIT-Fatigue) and hand grip strength (hand held
dynamometer) have established MCIDs; 3 units and
3 kg, respectively [93, 94]. For these secondary out-
comes, with our sample size of 62 per group we will
have approximately 35 % power for detecting the MCID
for fatigue and 96 % power for detecting the MCID for
hand grip strength, assuming SDs of these outcomes in
breast cancer survivors of 10.5 units [26, 95] and 4.5 kg
[96], respectively.
Primary and secondary outcomes
Summary descriptive statistics for demographic, social and
clinical data at baseline will be reported by allocated study
treatment. Continuous data will be summarized descrip-
tively using either mean and SD, or median and inter-
quartile range, depending on the distribution of the variable
of interest. Categorical data will be presented as frequencies
and percentages. Comparisons between the treatment
groups will be conducted to assess the degree to which
comparability of randomization was achieved. The baseline
between-group difference in the potentially influential
confounding variables (stage of disease, menopausal status,
treatment, pre-diagnosis weight, employment status and
educational level) will be examined. If any of these variables
are statistically significant at p < 0.001 they will be included
as co-variables in all outcome analyses.
The primary study outcome is the change in weight
(expressed as % of initial body weight) at 12 months.
The mean difference between treatment groups will be
calculated using linear mixed models with treatment
group (intervention/usual care) and time (0/12/18 months)
entered as fixed effects and patient entered as a random
effect. We will include an interaction effect between treat-
ment group and time in order to investigate change in
weight. The corresponding 95 % Wald confidence interval
and p-value will be reported. For secondary outcomes, the
effect estimates will be presented as a mean difference,
which will be calculated using a mixed effects linear
regression model. For all models the corresponding 95 %
Wald confidence interval and p-value will be reported.
Statistical significance will be set at p <0.05 (two-tailed)
and there will be no adjustment for multiple comparisons.
All analyses will be intention-to-treat, with all evaluable
data analysed according to the treatment group allocated.
To examine the sensitivity of results to attrition, ana-
lyses will be re-run after imputing missing data. The
type of imputation will be decided after the characteris-
tics of participants with missing data are compared
against the characteristics of those with complete data.
Either a single imputation method (using last observa-
tion carried forward) or a multiple imputation method
(using chained equations) will be selected. Further,
per-protocol analyses will be performed to compare
those completing at least 75 % of intervention calls with
those completing less intervention calls. Stratified ana-
lyses exploring effects on secondary outcomes based on
amount of weight loss achieved (≥5 % weight loss vs. < 5 %
weight loss) will be conducted.
Moderators and mediators of outcome
Exploratory analyses will be conducted to determine
whether there is moderation or mediation of interven-
tion effects. Moderator analysis will determine whether
intervention effects differ across demographic (e.g., age,
menopausal status) and breast cancer (e.g., receptor
status/subtype, chemotherapy treatment, fear of cancer
recurrence) characteristics and will be performed by con-
sidering the statistical significance of an interaction
between a potential moderator and the intervention using
a Wald test. Mediator analysis will determine whether
theoretically-driven constructs and mechanisms for be-
havior change do in fact mediate the intervention
effects. Potential mediators will be assessed using path
analysis. Point estimates and bootstrap confidence
intervals of path coefficients and the product of the
mediated path coefficients will be used to determine




Costs to deliver the intervention, not including the
research/assessment components, are used in the cost
analysis. They are tracked during trial implementation
and include the cost of coach time, intervention mate-
rials (workbook, self-monitoring diary, pedometer, digital
scale, measuring tape, kilojoule-calorie counter book)
and related infrastructure (i.e., office space, telephones,
computers and call costs).
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Incremental cost-effectiveness/analysis
The cost-effectiveness analysis will present results as
cost per health-adjusted life year (HALY) taking usual
care as comparison. An existing micro-simulation model
with a lifetime horizon (developed for the ACE Prevention
project [97, 98]) will be adapted for this purpose. Epi-
demiological data will be updated to 2013 using estimates
for Australia from the Global Burden of Disease study
[99]. Demographic and health-related data collected at
baseline and changes in weight and clinical biomarkers
will be used to estimate lifetime risks of cardiovascular
disease (based on sex, age, clinical biomarkers and body
composition) using calibrated Framingham equations
[100]. Other non-breast cancer health risks (diabetes
mellitus, osteoarthritis, colon cancer, endometrial cancer
and kidney cancer) will be modeled assuming that age-
specific Australian average rates apply. Breast cancer
recurrence risks and mortality will be modeled based on
best available evidence at the time of conducting the mod-
eling. We will take into account that after the 18-month
assessment, weight is regained at a rate of 0.02–0.03 kg/m2
per month [101] and assume commensurate waning of the
effects on clinical biomarkers. Years spent with disease will
be valued less than healthy years by applying disability
weights [102]. All of this will be used to calculate lifetime
HALYs for all participants in the intervention and usual
care groups. In both approaches, one-way sensitivity ana-
lysis and a combination of parametric and non-parametric
bootstrapping will be applied. Net costs will be estimated
from intervention costs and the modeled difference in
health care costs in the remaining lifetime between the
intervention and control groups. In both analyses, costing
will take a health sector perspective that includes costs to
patients and government. Costs associated with delivering
the intervention (e.g. coach time, intervention materials)
and costs incurred by participants (e.g., time) will be based
on trial information. Costs associated with the development
of the intervention will not be included. Costs of disease
treatment will be taken from the Australian Institute of
Health and Welfare’s Disease Costs and Impacts Studies.
As per common convention, participants’ time will be val-
ued at 25 % of the wage rate [103, 104].
Discussion
The Living Well after Breast Cancer trial is the first
large-scale randomized controlled trial of a weight loss
intervention versus usual care in Australian breast
cancer survivors. This trial adds to the international evi-
dence in breast cancer survivors on the effectiveness of
telephone-delivered weight loss interventions [17, 18,
105–107], which have greater potential for scaling-up
into routine practice [21, 108]. Further, this trial will
provide important evidence on the effect of weight loss
on a broad range of secondary outcomes, some of which
have not been examined in this population to date.
Pertinent to the uptake of such interventions as part of
routine follow-up care for breast cancer survivors, this
trial will include an analysis on the cost-effectiveness of
the intervention.
An additional strength of this study is the recruitment
of a broad sample of breast cancer survivors through
hospital clinics and the population-based cancer registry,
including both pre- and post-menopausal breast cancer
survivors and women with pre-existing comorbidities.
Participants were recruited as close to the end of treat-
ment as possible, which differs from many other weight
loss intervention trials in breast cancer survivors, where
participants were on average 3–5 years post-diagnosis at
study baseline [18, 19].
The trial is powered based on the primary outcome of
weight change. With the sample size it is powered to
detect medium or larger effect sizes in secondary out-
comes. For some secondary outcomes (e.g. fatigue),
smaller effect sizes may be clinically meaningful but the
trial will be underpowered to detect these. As a number
of the secondary outcomes have not been previously
examined in the context of a weight loss intervention in
breast cancer survivors, results from this trial will pro-
vide preliminary evidence on the effect of weight loss on
these outcomes. Due to the nature of the data collection
procedures, recruitment was limited to women living
within traveling distance of the capital city, therefore,
results may not generalize to women living in regional
and rural areas.
This trial will provide novel evidence on effectiveness
and cost-effectiveness of a telephone-delivered weight
loss intervention for breast cancer survivors. Findings
from this trial will help address a number of gaps identi-
fied by the American Society of Clinical Oncology [16]
and add to the evidence needed to inform the provision
of weight loss interventions to breast cancer survivors as
part of routine survivorship care.
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